CASTLE BIOSCIENCE DL-,001

Castle Biosciences will list its common stock on the newly established Nasdaq Texas in addition to its primary listing on the Nasdaq Global Market under the ticker CSTL. Trading on Nasdaq Texas begins today; the secondary listing is intended to expand tradability for investors without changing the company’s operations, reporting obligations, or capital structure. The company stresses its connection to Texas and views the listing as an additional channel for attracting investors. » More on de.investing.com

At the Canaccord growth conference, Castle Biosciences said its business is broadening: DecisionDx‑Melanoma continues to grow in the mid-to-high single digits, TissueCypher is becoming a larger revenue driver and AdvanceAD‑Tx showed strong order growth in Q2. The company raised its full-year outlook and expects positive adjusted EBITDA for the remainder of 2026 and for 2027. Management cited near-term headwinds from reimbursement delays, mainly for DecisionDx‑SCC and AdvanceAD‑Tx, but expects greater clarity and several catalysts in 2027. » More on de.investing.com

The New York State Department of Health has approved Castle Biosciences’ non‑invasive gene‑expression test AdvanceAD‑Tx, which assigns patients aged 12 and older with moderate-to-severe atopic dermatitis to a JAK inhibitor‑responder or Th2 molecular profile. The test evaluates 487 genes from skin swabs across 12 inflammatory and cutaneous signaling pathways and requires no biopsy. Castle thus holds NY approvals for its dermatology and ophthalmology portfolios and operates clinical labs in Phoenix and Pittsburgh; the stock trades at $23.12, yet analysts still see strong buy opportunities with price targets between $35 and $52. The company generated $340 million in revenue over the last twelve months with a 78% gross margin and has more cash than debt, but is not yet profitable. » More on de.investing.com